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Background:  The existence of an association between lung function and metabolic syndrome (MetS) has been debated in cases 
involving non-obese subjects. To address this debate, we performed a cross-sectional study to investigate the association between 
lung function and MetS in both obese and non-obese populations.
Methods:  The present study consisted of a total of 1,951 Korean male subjects. In this study group, we investigated relationships 
between lung function and MetS risk factors such as fasting serum glucose, systolic blood pressure (SBP), insulin resistance in-
dex, waist circumference (WC), and hemoglobin A1C level.
Results:  Forced vital capacity (FVC) values were significantly lower in the MetS group compared with those of the non-MetS 
group. In both non-obese (body mass index [BMI] < 25 kg/m
2) and obese subjects (BMI ≥ 25 kg/m
2), fasting serum glucose, he-
moglobin A1C level, insulin resistance index, SBP, WC, and the prevalences of diabetes and MetS were significantly higher in sub-
jects in the lowest FVC quartile compared with those in the highest FVC quartile. Odds ratios for the presence of MetS risk fac-
tors, after adjusting for age and height, ranged from 1.21 to 1.39 (P < 0.01) for a one standard deviation decrease in FVC.
Conclusion:  The results of our study suggest that decreased vital capacity in Korean adult male subjects is associated with MetS, 
irrespective of obesity.
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INTRODUCTION
Metabolic syndrome (MetS), a disorder involving impaired glu-
cose metabolism, dyslipidemia, hypertension, and central obe-
sity, is associated not only with type 2 diabetes mellitus and 
cardiovascular disease, but also with many other systemic dis-
orders such as chronic lung disease and fatty liver disease [1]. 
In Western countries, several reports have suggested that glu-
cose intolerance or diabetes, hypertension, and cardiovascular 
diseases are associated with impaired lung function [2-6].
  Recently, several studies have been published showing that 
decreased lung function is associated with MetS [1,7,8]. While 
these studies have demonstrated a positive relationship between 
decreased lung function and MetS [9,10], the relationship be-
tween vital capacity and MetS in non-obese subjects remains a 
matter of debate. In 2009, Oda and Kawai [11] reported that 
lower vital capacity is associated with diabetes but not with 
MetS in non-obese Japanese men, and that the association be-
tween lower vital capacity and diabetes in non-obese men may 
involve factors other than MetS or insulin resistance. Converse-
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ly, other studies have reported an association between lower 
vital capacity and MetS even in non-obese subjects, which sug-
gests that lower vital capacity may be associated with certain 
characteristics of metabolically obese subjects who are of nor-
mal weight [12,13].
  To our knowledge, few studies have addressed the relation-
ship between lung function and MetS in the Korean population 
[14]. Thus, we performed a cross-sectional study to investigate 
the relationship between lung function and MetS in both obese 
and non-obese Korean population. 
METHODS
Subjects and measurements
Data was collected from the Samsung Medical Health Promo-
tion Center between March 1 and July 31, 2008. During that 
time period, a total of 4,804 men and 4,192 women visited the 
medical center. Of these patients, we selected participants who 
were 30 years of age or older. The subjects meeting these crite-
ria were requested to fill out a questionnaire regarding their 
personal history of cardiovascular disease, smoking status, anti-
hypertensive medication, anti-lipid drugs, and hypoglycemic 
agents. Because many of the female patients were not available 
for answering questionnaire, the present study includes only 
male subjects. 
  Subjects with a history of lung cancer, lung or pleural sur-
gery, or chronic lung disease (chronic obstructive pulmonary 
disease or asthma) were excluded. To eliminate the effects of 
smoking on lung function, current smokers were excluded. 
Based on those exclusion criteria, the final sample population 
consisted of 1,951 non-smoking men.
  For the collection of blood samples, patients fasted over-
night, and blood was subsequently collected to measure serum 
glucose, triglycerides, high density lipoprotein cholesterol 
(HDL-C), low density lipoprotein cholesterol (LDL-C), hemo-
globin A1C (HbA1C), white blood cell count (WBC), electrolytes, 
high sensitivity C-reactive protein (hs–CRP), and insulin levels. 
Lung function tests including forced vital capacity (FVC) and 
forced expiratory volume in 1 second (FEV1) were performed 
using a pulmonary function test spirometer (Sensor Medics, 
Yorba Linda, CA, USA). The results of these tests were used to 
calculate FEV1/FVC. Body fat was measured using multifre-
quency bioelectrical impedance analysis using an inBody720 
(Biospace, Seoul, Korea). Average blood pressure was calculated 
from two measurements taken with the subject in a seated po-
sition, following 5 minutes of rest. Body weight was measured 
with subjects wearing light clothing provided by the testing 
center. Body mass index (BMI) was calculated as weight in kilo-
grams divided by the square of patient height in meters, and 
waist circumference (WC) was measured at the level of the 
umbilicus. The revised National Cholesterol Education Pro-
gram’s Adult Treatment Panel (NCEP-ATP III) criteria was 
used for definition of MetS, in which the presence of three or 
more of the following five components of MetS were consid-
ered a positive indicator for MetS [15]: 1) WC: a modified cut-
off point of 90 cm for men and 80 cm for women, which is con-
sistent with recommendations from the International Diabetes 
Federation for Asian individuals [16]; 2) blood pressure: a sys-
tolic blood pressure (SBP) ≥ 130 mm Hg and/or a diastolic blood 
pressure (DBP) ≥85 mm Hg; 3) triglycerides ≥ 150 mg/dL; 4) 
HDL-C < 40 mg/dL in men and < 50 mg/dL in women; and 5) 
fasting serum glucose ≥ 100 mg/dL. Subjects who were being 
treated with antihypertensive agents or hypoglycemic medica-
tions at the time of the study were considered to be positive for 
the respective component of the criteria described above. In ad-
dition, subjects were considered as having diabetes if their fast-
ing serum glucose was greater than or equal to 126 mg/dL and/
or if the subject was being treated with hypoglycemic medica-
tion at the time of evaluation. Subjects were considered posi-
tive for hypertension if they had already been prescribed med-
ication for hypertension or if their blood pressure measured 
SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg. Likewise, hyper-
triglyceridemia was defined as a serum triglyceride concentra-
tion of more than 150 mg/dL or if a subject was taking a pre-
scribed lipid-lowering agent at the time of evaluation. Obesity 
was defined as a BMI greater than 25 kg/m
2, while central obe-
sity was defined as a WC greater than 90 cm. Insulin resistance 
was estimated according to the homeostasis model assessment 
(HOMA) [17]. Subjects with a HOMA index greater than 2.52 
(75th percentile value for this study group) were defined as hav-
ing insulin resistance. Before initiating this study, approval was 
received from the Ethical Committee of Samsung Medical Cen-
ter at Sungkyunkwan University in Seoul, Korea.
Statistical analysis
Components of MetS and other clinical characteristics were 
compared between subjects with and without MetS. Subjects 
were divided into quartiles based on their FVC values (< 87, 
87-96, 96-104, ≥ 104%) and were further subdivided into non-
obese (BMI < 25 kg/m
2) and obese (BMI ≥ 25 kg/m
2) groups. 255
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MetS risk factors, prevalence of diabetes, presence of MetS, 
and other characteristics were compared between subjects in 
the lowest and highest FVC quartiles in both the non-obese and 
obese groups. Partial correlation coefficients between FVC and 
MetS components were calculated for all subjects. The number 
of MetS components was evaluated and categorized into six 
groups: group 0 (n = 439), group 1 (n = 500), group 2 (n = 389), 
group 3 (n = 326), group 4 (n = 219), and group 5 (n = 78), ac-
cording to the number of MetS components.
  The data obtained from the subjects were analyzed such 
that a multilinear regression analysis was performed, in which 
FVC was the dependent variable and MetS components were 
the independent variables. In addition, logistic regression analy-
sis was performed to estimate the odds ratio for the presence 
of MetS components, where a 12% (1 SD) decrease in FVC 
was assumed. Statistical analysis was performed using PASW 
17.0 software (SPSS Inc., Chicago, IL, USA), and values of P < 
0.05 were considered statistically significant.
RESULTS
The mean subject age was 52.2 ± 8.8 years, and the mean BMI 
and WC of the subjects were 23.8 ± 3.0 kg/m
2 and 86.2 ± 6.9 cm, 
respectively. The prevalences of diabetes, MetS, hypertension, 
and cardiovascular diseases were 10.4%, 31.9%, 26.1%, and 
3.1%, respectively. Basal characteristics and MetS components 
for MetS and non‐MetS subjects are shown in Table 1. With 
the exception of HDL‐C, all MetS components were significant-
Table 1.  Baseline characteristics of the subjects according to metabolic syndrome status
Variable
No metabolic syndrome
(n = 1,328)
Metabolic syndrome
(n = 623)
P value
a
Age, yr 51.0 ± 8.3 54.8 ± 9.4 < 0.01
BMI, kg/m
2 23.6 ± 2.9 24.1 ± 3.1 < 0.01
Fasting plasma glucose, mg/dL 94.6 ± 10.2 113.5 ± 26.8 < 0.01
Body fat, % 26.8 ± 7.1 27.1 ± 6.1 NS
Waist circumference, cm 84.5 ± 6.2 89.9 ± 6.9 < 0.01
Systolic blood pressure, mm Hg 118.4 ± 12.6 126.7 ± 13.5 < 0.01
Diastolic blood pressure, mm Hg 76.2 ± 9.1 80.1 ± 9.4 < 0.01
Total cholesterol, mg/dL 198.8 ± 31.8 198.7 ± 35.8 NS
Triglycerides, mg/dL 123.7 ± 62.7 183.9 ± 104.2 < 0.01
HDL-C, mg/dL 52.6 ± 12.2 45.7 ± 11.7 < 0.01
LDL-C, mg/dL 126.8 ± 28.1 125.6 ± 31.5 NS
Hemoglobin A1c, % 5.4 ± 0.4 6.1 ± 1.1 < 0.01
Insulin resistance (HOMA index) 1.9 ± 0.9 2.5 ± 1.3 < 0.01
Fasting insulin, mIU/mL 8.3 ± 3.6 9.1 ± 4.0 < 0.01
FVC, % 97.0 ± 11.5 93.1 ± 12.1 < 0.01
FEV1, % 106.1 ± 13.6 102.6 ± 14.5 < 0.01
FEV1/FVC ratio, % 81.8 ± 6.1 82.0 ± 5.9 NS
Anti-hypertensive medication 79 (4.0) 268 (13.6) < 0.01
Anti-diabetic medication 10 (0.5) 165 (8.4) < 0.01
Diabetes 19 (1.0) 185 (9.4) < 0.01
Hypertension 181 (9.3) 331 (16.9) < 0.01
Cardiovascular disease 21 (1.1) 40 (2.1) < 0.01
Data are presented as number (%) or mean ± standard deviation unless otherwise indicated.
BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FVC, forced vital capacity; 
FEV1, forced expiratory volume in 1 second; HOMA, homeostasis model assessment; NS, not significant.
aP values were calculated using the t-test (continuous variables) or chi-square test (categorical variables).256
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ly higher in the MetS subjects than in the non‐MetS subjects. A 
significantly greater number of subjects with MetS were found 
to be taking anti‐hypertensive medication or oral hypoglyce-
mic agents or were diagnosed with cardiovascular diseases 
than those in the non‐MetS group. Likewise, FVC and FEV1 
were significantly lower in the MetS group compared with those 
of subjects in the non‐MetS group; however, the FEV1/FVC 
ratios did not differ significantly between the MetS and non–
MetS groups (Table 1). The FVC, FEV1, and FEV1/FVC were 
also compared between the diabetes and non‐diabetes groups. 
Values of FVC and FEV1 were significantly lower in the diabetic 
subjects than they were in the non‐diabetic subjects (92.0 ± 
11.2% vs. 96.2 ± 11.8%, 101.2 ± 13.3% vs. 105.5 ± 13.9%, respec-
tively; P < 0.05); however the FEV1/FVC did not differ signifi-
cantly (81.7 ± 6.2% vs. 81.9 ± 5.9%; P = NS). 
  After adjusting for age and height, FVC values were nega-
tively correlated with MetS components such as fasting serum 
glucose, triglycerides, SBP, WC, and HOMA index. Conversely, 
FVC was positively correlated with BMI and HDL‐C (Table 2).
  In non‐obese subjects, fasting serum glucose, WC, HbA1C, 
insulin resistance index, SBP, and HDL‐C, as well as the preva-
lences of diabetes, hypertension, and MetS were significantly 
higher; however, BMI was lower in subjects in the lowest FVC 
quartile compared to that of those in the highest FVC quartile 
(Table 3). In obese subjects, fasting serum glucose, body fat, 
WC, HbA1C, insulin resistance, fasting serum insulin level, SBP, 
BMI, and the prevalences of diabetes, hypertension, and MetS 
were significantly higher in subjects in the lowest FVC quartile 
compared to those of individuals in the highest FVC quartile 
(Table 4).
  The FVC and FEV1 results according to the number of MetS 
components were as follows: group 0 (97.6 ± 12.0%, 106.5 ± 
14.5%, respectively), group 1 (96.5 ± 11.4%, 105.9 ± 12.9%), 
group 2 (96.3 ± 11.3%, 105.2 ± 13.4%), group 3 (94.3 ± 12.1%, 
103.4 ± 14.6%), group 4 (93.4 ± 11.9%, 104.1 ± 14.7%), and 
group 5 (90.7 ± 12.3%, 99.8 ± 13.9%). Based on these results, 
there appears to be a trend for FVC and FEV1 to decrease with 
an increasing number of MetS components. While there was 
no significant difference between groups 1 and 2, a significant 
difference between groups 2 and 3 was observed. Thus, having 
three or more MetS components appeared to be related to sig-
nificant declines in FVC and FEV1. 
  The results of our multi‐variable linear regression analysis, 
all metabolic components were entered into the model, using 
FVC as dependent variables are shown in Table 5. The HOMA 
index, SBP, and WC appeared to be negatively correlated with 
FVC after adjusting for age and height; however, fasting serum 
glucose and triglycerides did not appear to be correlated with 
FVC.
  In our logistic regression analysis, after adjusting for age 
and height, an FVC decrease of 12% (1 SD) appeared to be as-
sociated with increases in type 2 diabetes mellitus (odds ratio 
[OR], 1.39 [1.19 to 1.62]), hypertension (OR, 1.22 [1.10 to 1.36]), 
insulin resistance (OR, 1.31 [1.18 to 1.46]), abdominal obesity 
(OR, 1.21 [1.10 to 1.34]), and hypertriglyceridemia (OR, 1.21 
[1.10 to 1.32]). However, obesity and cardiovascular disease 
did not appear to be associated with a decrease in FVC.
DISCUSSION
The present study showed a cross-sectional relationship be-
tween lung function and MetS in both obese and non-obese 
males. In the MetS group, both FVC and FEV1 values, but not 
the FVC/FEV1 ratio, were lower than those of subjects in the 
non-MetS group. The present study also showed that having 
three or more MetS components result in a significant decrease 
in FVC. 
  Currently, it is thought that there is a common mechanism 
underlying MetS, such as insulin resistance and/or obesity 
[18,19]. Previous studies have reported that fasting serum in-
sulin levels and insulin resistance are inversely correlated with 
FVC and FEV1 [3,20]. Our study showed that fasting serum 
Table 2. Partial correlations between percentage of forced vital 
capacity (FVC) and metabolic risk factors
Variable
FVC (n = 1,951)
Correlation coefficient P value
Fasting glucose -0.10 < 0.01
Triglyceride -0.06 < 0.05
HDL-C 0.05 < 0.05
Systolic blood pressure -0.08 < 0.01
Waist circumference -0.10 < 0.01
HOMA index -0.12 < 0.01
Fasting insulin -0.10 < 0.01
Body mass index 0.07 < 0.01
Body fat -0.09 < 0.01
HbA1C -0.11 < 0.01
The model was adjusted for age and height.
HDL-C, high density lipoprotein cholesterol; HOMA, homeostasis 
model assessment.257
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insulin and insulin resistance (HOMA) are also inversely cor-
related with FVC and FEV1. In addition, obesity has been shown 
to be inversely related to lung function [21]. Consistent with 
previous studies, we observed that WC appears to be negatively 
correlated with FVC and FEV1 in both obese and non-obese 
males, but BMI appears to be positively correlated with FVC 
and FEV1. However, in individuals with a BMI greater than 25 
kg/m
2, a negative correlation with FVC and FEV1 was observed 
(data not shown), also in agreements with the results of previ-
ous studies [12]. Based on these results, we suggest that, in 
general, a higher BMI may be associated with a higher body fat 
percentage; however, in the case of subjects whose BMI is less 
than 25 kg/m
2, a higher BMI may arise from increased levels 
of lean tissue, such as muscle mass. Together, central obesity 
and insulin resistance, rather than BMI alone, may play an im-
portant role in decreases in lung function, especially with re-
spect to FVC. Recently, Oda and Kawai [11] reported that a 
lower vital capacity is associated with diabetes but not with 
MetS in non-obese subjects. Specifically, they found that a lower 
vital capacity was associated with a lower BMI in non-obese 
Japanese, and that the association between lower vital capacity 
and diabetes in non-obese Japanese may involve factors other 
than MetS or insulin resistance. However, in our study, we 
found that lower FVC values were associated with MetS and 
diabetes in non-obese individuals, despite the lower BMI in 
the lowest FVC quartile compared to that in the highest FVC 
quartile. In the non-obese group, fasting serum glucose, HbA1C 
level, SBP, insulin resistance index, and the prevalences of dia-
betes, hypertension, and MetS were significantly higher in sub-
jects in the lowest FVC quartile compared to those of subjects 
Table 3. Basal characteristics and metabolic components of the subjects according to quartile of forced vital capacity (FVC) in 
the non-obese group (< 25 kg/m
2)
FVC quartile
< 87%
(n = 129)
87-96%
(n = 189)
96-104%
(n = 158)
≥ 104%
(n = 165)
P value
Age, yr 52.3 ± 9.3 53.5 ± 8.9 51.6 ± 9.0 52.1 ± 8.5 NS
BMI, kg/m
2 21.6 ± 2.1 22.1 ± 2.0 22.5 ± 1.7 22.4 ± 1.6 < 0.01
Fasting glucose, mg/dL 103.5 ± 23.1 99.9 ± 19.1 98.9 ± 15.6 97.4 ± 15.1 < 0.05
Body fat, % 25.4 ± 5.6 25.4 ± 6.2 24.6 ± 6.1 25.6 ± 6.0 NS
WC, cm 86.2 ± 7.2 84.9 ± 6.6 84.8 ± 6.4 84.4 ± 6.4 < 0.01
SBP, mm Hg 122.9 ± 12.9 119.9 ± 13.9 120.8 ± 14.1 120.0 ± 12.2 < 0.01
DBP, mm Hg 78.4 ± 9.1 76.5 ± 9.6 77.5 ± 9.9 77.4 ± 8.5 NS
Total cholesterol, mg/dL 197.9 ± 35.1 199.0 ± 32.8 196.2 ± 34.1 200.3 ± 31.7 NS
Triglycerides, mg/dL 148.9 ± 23.2 135.5 ± 69.6 133.4 ± 77.3 134.3 ± 79.6 < 0.05
HDL-C, mg/dL 49.6 ± 12.8 51.1 ± 12.4 51.8 ± 12.7 52.1 ± 13.3 < 0.05
Hemoglobin A1c, % 5.8 ± 1.0 5.6 ± 0.7 5.6 ± 0.7 5.4 ± 0.6 < 0.01
Insulin resistance 2.0 ± 0.9 2.0 ± 0.9 1.9 ± 0.8 1.8 ± 0.8 < 0.01
Fasting insulin, mIU/mL 7.7 ± 3.1 8.1 ± 3.0 7.7 ± 2.7 7.4 ± 2.8 NS
FVC, % 80.0 ± 5.3 91.2 ± 2.6 99.4 ± 2.3 110.9 ± 5.4 < 0.01
FEV1, % 89.1 ± 9.1 100.2 ± 7.4 108.5 ± 7.9 120.1 ± 9.7 < 0.01
FEV1/FVC ratio, % 84.1 ± 7.2 82.1 ± 6.3 81.7 ± 5.9 80.7 ± 4.9 NS
Anti‐hypertensive medication, % 19.0 13.8 14.0 14.0 NS
Anti‐diabetic medication, % 13.4 7.5 8.5 3.7 < 0.05
Diabetes, % 14.1 8.4 9.6 5.8 < 0.05
Hypertension, % 30.5 24.0 23.6 20.7 < 0.05
Cardiovascular diseases, % 3.0 3.3 1.5 2.7 NS
Metabolic syndrome, % 40.7 24.6 26.5 21.3 < 0.01
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein 
cholesterol; FEV1, forced expiratory volume in 1 second; NS, not significant.258
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in the highest FVC quartile. These differences may be explained 
by studying the high prevalence of MetS in our study group 
(21.3 to 40.3%) as compared to that of the Oda and Kawai 
study group (4.7 to 4.8%). Likewise, WC values also were higher 
in our group (84.0 to 86.0 cm) than they were in the Oda and 
Kawai group (80.0 to 81.9 cm) [11,22]. As in previous reports 
[12], our study also suggested that a lower FVC may be associ-
ated with characteristics of metabolically obese subjects who 
are of normal weight [13].
  Abdominal obesity was a better predictor of pulmonary 
function than BMI is. This association may result from the me-
chanical effects of abdominal obesity, which may mechanically 
affect compliance of the diaphragm and chest wall [23]. Fur-
ther, abdominal obesity is linked to the metabolic effects of 
obesity, in that adiposity is a low-grade inflammatory condi-
Table 5. Multivariable linear regression analysis of the rela-
tionships between forced vital capacity (FVC) and metabolic 
risk factors
Variable
FVC (n = 1,951)
B P value
a
Insulin resistance (HOMA index) ‐1.82 < 0.01
Waist circumference ‐0.18 < 0.01
Systolic blood pressure ‐0.05 < 0.01
Fasting glucose ‐0.01 NS
Triglyceride ‐0.00 NS
Body mass index 0.61 < 0.01
The model was adjusted for age and height.
B Standard regression coefficient.
HOMA, homeostasis model assessment; NS, not significant.
aP values were calculated using multiple regression analysis.
Table 4. Basal characteristics and metabolic components of the subjects according to quartile of forced vital capacity (FVC) in 
the obese group (≥ 25 kg/m
2)
FVC quartile
< 87%
(n = 129)
87-96%
(n = 189)
96-104%
(n = 158)
≥ 104%
(n = 165)
P value
Age, yr 53.0 ± 8.9 52.5 ± 9.0 51.0 ± 8.3 51.2 ± 7.8 NS
BMI, kg/m
2 27.4 ± 2.3 27.1 ± 2.1 27.0 ± 1.8 26.8 ± 1.8 < 0.01
Fasting glucose, mg/dL 105.0 ± 23.6 102.0 ± 22.1 101.9 ± 22.2 100.1 ± 16.5 < 0.05
Body fat, % 31.9 ± 6.8 29.5 ± 7.0 29.6 ± 7.2 29.2 ± 7.3 < 0.01
WC, cm 90.3 ± 6.7 88.0 ± 7.7 88.6 ± 6.3 87.4 ± 6.2 < 0.01
SBP, mm Hg 124.1 ± 14.9 121.6 ± 13.9 123.5 ± 13.5 119.1 ± 12.1 < 0.01
DBP, mm Hg 78.4 ± 9.5 77.2 ± 9.7 78.7 ± 9.9 76.3 ± 9.1 NS
Total cholesterol, mg/dL 202.3 ± 34.5 196.2 ± 33.0 202.4 ± 31.4 198.1 ± 31.1 NS
Triglycerides, mg/dL 162.4 ± 85.1 152.6 ± 98.3 149.1 ± 70.2 151.7 ± 98.5 NS
HDL-C, mg/dL 47.7 ± 10.5 49.0 ± 10.7 48.1 ± 11.5 49.8 ± 13.3 NS
Hemoglobin A1c, % 5.9 ± 0.9 5.7 ± 0.8 5.6 ± 0.8 5.5 ± 0.6 < 0.01
Insulin resistance 3.0 ± 1.7 2.7 ± 1.5 2.5 ± 1.0 2.3 ± 1.0 < 0.01
Fasting insulin, mIU/mL 11.4 ± 5.4 10.8 ± 5.4 9.9 ± 3.4 9.2 ± 3.6 < 0.01
FVC, % 80.1 ± 5.1 91.1 ± 2.6 99.3 ± 2.3 111.2 ± 5.6 < 0.01
FEV1, % 89.1 ± 8.5 99.7 ± 7.0 109.4 ± 7.6 120.8 ± 10.2 < 0.01
FEV1/FVC ratio, % 82.7 ± 5.6 81.2 ± 5.5 81.8 ± 5.4 80.6 ± 5.4 < 0.01
Anti‐hypertensive medication, % 27.9 21.7 24.1 19.4 NS
Anti‐diabetic medication, % 14.7 10.1 10.8 6.7 < 0.05
Diabetes, % 18.6 11.6 12.7 7.3 < 0.05
Hypertension, % 34.9 28.0 34.2 21.8 < 0.01
Cardiovascular diseases, % 4.7 5.3 1.9 4.8 NS
Metabolic syndrome, % 48.8 41.8 38.0 32.7 < 0.01
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein 
cholesterol; FEV1, forced expiratory volume in 1 second; NS, not significant.259
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tion that is linked to insulin resistance. Visceral adipose tissue 
influences adipokines and cytokines, such as interleukine 6 
and tumor necrosis factor-α. These cytokines may cause sys-
temic inflammation, which is thought to be involved in the as-
sociation between central obesity and/or insulin resistance and 
pulmonary function [24].
  In our multi-linear regression analysis, insulin resistance, as 
measured by the HOMA index, appeared to be independently 
associated with FVC after adjusting for age, height, and MetS 
components. This result suggests that the relationship between 
insulin resistance and FVC is independent of abdominal obe-
sity, which is itself a risk factor for the development of insulin 
resistance and a mechanical factor that may lead to impaired 
lung function. As shown in other reports, there are additional 
known factors that correlate with insulin resistance, such as 
hypertension and diabetes, all of which are inversely correlat-
ed with FVC [3,5,6]. However, the underlying mechanism of 
decreased lung function may be multi-factorial. Our study was 
not controled for several potential confounding factors, such 
as physical activity, socio-economic status, or alcohol intake. 
These potential confounding factors may explain our low cor-
relation coefficient.
  Previous reports have shown that impaired lung function 
can predict the developments of diabetes, insulin resistance, 
hypertension, and cardiovascular disease [4,6,20]. In our study, 
we inferred that a decrease in FVC was associated with increased 
risks of type 2 diabetes, hypertension, insulin resistance, hyper-
triglyceridemia, and central obesity; however, unlike other stud-
ies, no relationship between decreased lung function and cardio-
vascular disease was found. The reason for this lack of an asso-
ciation may have been due to the low incidence of cardiovas-
cular disease in our study subjects. Our study also found no in-
crease in the risk of obesity with decreased lung function. To-
gether, these results suggest that it is not simply obesity, but 
rather insulin resistance and/or central obesity are more im-
portant causes of decreased lung function.
  Our study was performed on a limited cross-section of the 
population, using only male subjects, and was not controlled 
for potential biases from physical activity and alcohol consump-
tion. Thus, a longitudinal prospective study that includes fe-
male subjects will be needed to establish the relationship be-
tween lung function and MetS. 
  In summary, insulin resistance and certain components of 
MetS (type 2 diabetes mellitus, hypertension, central obesity, 
and hypertriglyceridemia) appear to be related to vital capaci-
ty, irrespective of obesity, in Korean males. These findings sug-
gest that there is a relationship between a lower FVC and MetS 
in non-obese subjects, which may also be associated with met-
abolically obese subjects of normal weight.
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